This CME Activity has expired and is no longer available for credit.
A Call to Action: Optimal Diagnosis and Treatment of IBD in the Older Adult
Time to Complete
September 17, 2012
September 17, 2013
1.00 / AMA PRA Category 1 Credit(s)TM
Jointly sponsored by
Support for this activity has been provided through an educational grant from Abbott, Aptalis, UCB, and Warner Chilcott.
As members of the Baby Boomer generation enter their 60s, it is reasonable to anticipate that clinicians will face an increase in the number of older patients with inflammatory bowel disease (IBD). Older patients with IBD can be a particular challenge for the practicing clinician, because they often present such issues as extensive differential diagnoses, comorbidities, polypharmacy, and poor patient adherence. These challenges complicate medical management and worsen patient outcomes. In this interactive activity, the faculty presents a series of clinical discussions on the diagnosis and treatment of older patients with IBD and delivers information that will help clinicians to improve the IBD care they provide and achieve better outcomes for their older IBD patients.
This activity has been designed to meet the educational needs of gastroenterologists and other health care professionals involved in the care of older patients with IBD.
Upon completion of this activity, participants should be able to:
Discuss the differential diagnosis of IBD in older patients
Employ strategies for accurately diagnosing IBD in older patients
Explain factors that affect the safe use of IBD therapeutic agents in older patients
Design effective strategies to treat active disease and maintain remission of IBD in older patients
Seymour Katz, MD—Activity Chair Clinical Professor of Medicine Albert Einstein College of Medicine Bronx, New York
Seymour Katz, MD, has disclosed the following relevant financial relationships: Consultant/Scientific Advisor: Abbott, UCB Research/Clinical Trial Support: Abbott, Amgen, AstraZeneca, Braintree, Bristol-Myers Squibb, Centocor, Dr. Falk, Eisai, Forest, Frontage, Furiex, Genentech, Human Genome Sciences, Hutchison MediPharma, Luitpold Pharmaceuticals, Merck, Millennium, Otsuka, Pfizer, Proctor & Gamble, Prometheus, Salix, Tioga Pharmaceuticals, Tsumura, UnitedBioSource, University of Pennsylvania, XenoPort, Yale Speakers' Bureau: UCB, Warner Chilcott
Dr. Katz discusses the unlabeled or investigational use of a commercial product.
Darrell S. Pardi, MD Professor of Medicine Mayo Clinic Rochester, Minnesota
Darrell S. Pardi, MD, has disclosed the following relevant financial relationships: Advisory Board: Pfizer Consultant: Optimer
Christina M. Surawicz, MD Professor of Medicine University of Washington School of Medicine Seattle, Washington
Christina M. Surawicz, MD, has disclosed no relevant financial relationships.
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below.
Curatio CME Institute Disclosure
Denise C. LaTemple, PhD, President, has disclosed no relevant financial relationships. Jonathan S. Simmons, ELS, Senior Managing Editor, has disclosed no relevant financial relationships.
Penn State College of Medicine Disclosure
Faculty and staff involved in the planning and review of this activity have nothing to disclose.
The Internet was selected as the instructional format to accommodate the learning preferences of a significant portion of the intended audience.
UNAPPROVED PRODUCT USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, Penn State College of Medicine, Abbott, Aptalis, UCB, and Warner Chilcott do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Curatio CME Institute, Penn State College of Medicine, Abbott, Aptalis, UCB, or Warner Chilcott. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Method of Participation: There are no fees for participating in this CME activity. To receive credit during the period September 17, 2012 to September 17, 2013, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.
To obtain a certificate, participants must receive a score of 70% or better on the post-test. The post-test can be accessed at the end of the activity. For questions concerning the CME credits, contact Penn State College of Medicine at ContinuingEd@hmc.psu.edu or 717-531-6483 and refer to course # G5088-12-T.
Curatio CME Institute collects the information provided by the user. The information is used to notify users about upcoming programs and educational information that may be of interest. The information is not shared or used for commercial purposes unless prior permission has been granted by the user.
Curatio CME Institute may collect standard Web traffic data such as time and date of visit. Curatio CME Institute uses this information to administer its Web site. Browsing activity is recorded to form aggregate and anonymous demographic information, which is used as described above. Curatio CME Institute does not sell or offer to sell any user data, including registration and billing information, to any third parties for commercial purposes. Curatio CME Institute does, when required, provide the minimum subset of information to third parties that are responsible for accreditation of and issuance of certification for CME/CE tests. By participating in the Web-based activity, the user agrees that Curatio CME Institute has full permission to provide this minimum subset of information to the third parties as required by law.